Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
Franchi F, Schneider DJ, Prats J, Fan W, Rollini F, Been L, Taatjes-Sommer HS, Bhatt DL, Deliargyris EN, Angiolillo DJ. Franchi F, et al. Among authors: deliargyris en. J Thromb Thrombolysis. 2022 Oct;54(3):373-381. doi: 10.1007/s11239-022-02687-5. Epub 2022 Aug 29. J Thromb Thrombolysis. 2022. PMID: 36036856 Free PMC article. Clinical Trial.
Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ. Stone GW, et al. Among authors: deliargyris en. J Am Coll Cardiol. 2014 Jan 7-14;63(1):15-20. doi: 10.1016/j.jacc.2013.09.027. Epub 2013 Oct 16. J Am Coll Cardiol. 2014. PMID: 24140664 Free article. Clinical Trial.
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. White HD, et al. Among authors: deliargyris en. JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703887 Free article. Clinical Trial.
Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Pinto DS, Kohli P, Fan W, Kirtane AJ, Kociol RD, Meduri C, Deliargyris EN, Prats J, Reynolds MR, Stone GW, Michael Gibson C. Pinto DS, et al. Among authors: deliargyris en. Catheter Cardiovasc Interv. 2016 Feb 15;87(3):363-73. doi: 10.1002/ccd.26023. Epub 2015 May 22. Catheter Cardiovasc Interv. 2016. PMID: 26011467
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Gutierrez JA, et al. Among authors: deliargyris en. Eur Heart J. 2016 Apr 7;37(14):1122-30. doi: 10.1093/eurheartj/ehv498. Epub 2015 Sep 23. Eur Heart J. 2016. PMID: 26400827 Free PMC article. Clinical Trial.
Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database.
Kimmelstiel C, Pinto D, Aronow HD, Weintraub AR, Dangas G, Fan W, Prats J, Deliargyris EN, Katzen BT. Kimmelstiel C, et al. Among authors: deliargyris en. Circ Cardiovasc Interv. 2016 Jan;9(1):e002823. doi: 10.1161/CIRCINTERVENTIONS.115.002823. Circ Cardiovasc Interv. 2016. PMID: 26747849
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. O'Donoghue ML, et al. Among authors: deliargyris en. Circulation. 2016 Jan 19;133(3):248-55. doi: 10.1161/CIRCULATIONAHA.115.017300. Circulation. 2016. PMID: 26762525 Free PMC article. Clinical Trial.
Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.
Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van 't Hof A, Prats J, Bernstein D, Deliargyris EN, Stone GW. Dangas GD, et al. Among authors: deliargyris en. Circ Cardiovasc Interv. 2016 May;9(5):e003272. doi: 10.1161/CIRCINTERVENTIONS.115.003272. Circ Cardiovasc Interv. 2016. PMID: 27165710 Clinical Trial.
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Vaduganathan M, et al. Among authors: deliargyris en. Circ Cardiovasc Interv. 2016 Jun;9(6):e003612. doi: 10.1161/CIRCINTERVENTIONS.116.003612. Circ Cardiovasc Interv. 2016. PMID: 27313282 Free PMC article. Clinical Trial.
125 results